PR99856

MOUNTAIN VIEW, Calif., March 30, 2023 /PRNewswire=KYODO JBN/ --

Turn Biotechnologies, a cell rejuvenation company developing novel mRNA

medicines to cure untreatable, age-related conditions, announced that it will

for the first time share new data for its revolutionary dermatology platform

with the international regenerative aesthetic community.

Photo -

https://mma.prnewswire.com/media/2043671/sebastiano_campus_high_resolution.jpg

Logo - https://mma.prnewswire.com/media/1935529/TURN_LOGO_HI_RES_Logo.jpg

Evidence-based data showing the global regenerative efficacy of Turn Bio's

Epigenetic Reprogramming of Aging (ERA (TM)) technology on human skin cells

will be shared at the Aesthetic and Anti-aging World Congress, the leading

international conference specializing in aesthetic regenerative and anti-aging

medicine.

Turn Bio's co-founder and head of research Vittorio Sebastiano, PhD, will

provide insights on stem cell exhaustion and discuss how the company's ERA(TM)

technology can rejuvenate cells and restore cellular function in skin. The

workshop (https://c212.net/c/link/?t=0&l=en&o=3823807-1&h=633127790&u=https%3A%2F%2Fagenda.euromedicom.com%2Fglobal%2Fo%2Famwc-2023%2F2023-03-31%2F6639&a=workshop) will take place on March 31,

from 9 a.m. to 10:30 a.m. CET in the Camille

Blanc Auditorium at the Grimaldi Forum in Monaco.

The latest Turn Bio dermatology data will also be discussed in presentations by

several dermatology key opinion leaders during scientific sessions chaired by

internationally recognized experts in the field.

ABOUT TURN BIOTECHNOLOGIES

Turn Bio is a pre-clinical-stage company focused on repairing tissue at the

cellular level and developing transformative drug delivery systems. The

company's proprietary mRNA platform technology, ERA(TM) (Epigenetic

Reprogramming of Aging), restores optimal gene expression by combatting the

effects of aging in the epigenome. This restores cells' ability to prevent or

treat disease and heal or regenerate tissue. It will help to fight incurable

chronic diseases. Its eTurna(TM) Delivery Platform uses unique formulations to

precisely deliver cargo to specific organs, tissues, and cell types.

The company is completing pre-clinical research on tailored therapies targeting

indications in dermatology and immunology, and developing therapies for

ophthalmology, osteo-arthritis, and the muscular system. For more information,

see www.turn.bio (https://c212.net/c/link/?t=0&l=en&o=3823807-1&h=3152720161&u=http%3A%2F%2Fwww.turn.bio%2F&a=www.turn.bio).

FOR MORE INFORMATION, CONTACT:

Jim Martinez, rightstorygroup

jim@rightstorygroup.com or +1 (312) 543-9026

Source -  Turn Biotechnologies, Inc.